Skip to main content
Clinical Trials/NCT00732849
NCT00732849
Completed
Phase 4

The Impact of the Type and Route of Nutritional Support on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial.

Jagiellonian University1 site in 1 country600 target enrollmentJune 2002

Overview

Phase
Phase 4
Intervention
Reconvan, Dipeptiven, Omegaven
Conditions
Gastrointestinal Surgery
Sponsor
Jagiellonian University
Enrollment
600
Locations
1
Primary Endpoint
Immunonutrition and enteral nutrition would reduce the incidence of infectious complications in a population of malnourished patients
Status
Completed
Last Updated
17 years ago

Overview

Brief Summary

The study was designed to test the hypothesis that immunonutrition and enteral nutrition would reduce the incidence of infectious complications in a population of malnourished patients following elective upper GI surgery

Detailed Description

All patients qualified between June 2002 and December 2007 to total and distal subtotal gastrectomy or pancreaticoduodenectomy were screened for eligibility to participate in the study. Malnutrition was defined by the Nutritional Risk Index (NRI), calculated according to the formula used in the Veterans Administration Cooperative Group trial.{, 1991 #70} Additional eligibility criteria included: age between 18 and 80 years, Karnofsky performance status score of 80 or more, and adequate organ function measured by routine blood tests. Patients without features of malnutrition, as well as those with disseminated tumors, serious comorbidities (American Society of Anesthesiologists risk class of 4 or 5), and renal or liver failure were excluded. The study was designed to test the hypothesis that immunonutrition and enteral nutrition would reduce the incidence of infectious complications in a population of malnourished patients following elective upper GI surgery. Therefore, patients were randomly assigned in a 2×2 factorial design to four groups receiving immunostimulating versus normal diets, and enteral versus intravenous nutritional support. The secondary objective of the study was to evaluate the effect of nutritional intervention on overall morbidity and mortality rates, and the length of hospital stay.

Registry
clinicaltrials.gov
Start Date
June 2002
End Date
November 2007
Last Updated
17 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Jagiellonian University

Eligibility Criteria

Inclusion Criteria

  • age between 18 and 80 years,
  • Karnofsky performance status score of 80 or more,
  • adequate organ function measured by routine blood tests

Exclusion Criteria

  • patients \<18 or \> 80
  • Karnofsky performance \< 50

Arms & Interventions

4

Immunomodulating Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes + Omegaven (Fresenius Kabi), Dipepitven (Fresenius Kabi)

Intervention: Reconvan, Dipeptiven, Omegaven

1

Standard Enteral Nutrition - Peptisorb, Nutricia Ltd.

Intervention: Reconvan, Dipeptiven, Omegaven

2

Standard Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes

Intervention: Reconvan, Dipeptiven, Omegaven

3

Immunomodulating Enteral Nutrition: Reconvan, Fresenius Kabi Poland

Intervention: Reconvan, Dipeptiven, Omegaven

Outcomes

Primary Outcomes

Immunonutrition and enteral nutrition would reduce the incidence of infectious complications in a population of malnourished patients

Time Frame: Immunonutrition

Secondary Outcomes

  • To evaluate the effect of nutritional intervention on overall morbidity and mortality rates, and the length of hospital stay(morbidity)

Study Sites (1)

Loading locations...

Similar Trials